KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Inventory (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Change in Inventory for 5 consecutive years, with $870000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Change in Inventory fell 28.69% year-over-year to $870000.0, compared with a TTM value of $3.8 million through Mar 2025, up 36.17%, and an annual FY2025 reading of $1.6 million, down 60.64% over the prior year.
  • Change in Inventory was $870000.0 for Q1 2025 at Biocryst Pharmaceuticals, down from $2.2 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $3.4 million in Q3 2023 and bottomed at -$907000.0 in Q4 2023.
  • Average Change in Inventory over 3 years is $720444.4, with a median of $870000.0 recorded in 2025.
  • Peak annual rise in Change in Inventory hit 1031.3% in 2024, while the deepest fall reached 55.11% in 2024.
  • Year by year, Change in Inventory stood at -$907000.0 in 2023, then skyrocketed by 338.48% to $2.2 million in 2024, then tumbled by 59.78% to $870000.0 in 2025.
  • Business Quant data shows Change in Inventory for BCRX at $870000.0 in Q1 2025, $2.2 million in Q4 2024, and $1.5 million in Q3 2024.